• Quince Therapeutics reported Phase 2a results for inhaled rapamycin candidate LAM-001 in pulmonary arterial hypertension, including pulmonary hypertension tied to interstitial lung disease, with data already presented at the American Thoracic Society conference.
• The open-label add-on study showed clinically meaningful improvement or stabilization across exercise capacity, pulmonary blood-flow measures, cardiac-stress biomarkers, lung function, with patients also moving to a better functional class by the end of treatment.
• LAM-001 was generally well tolerated on top of standard of care in evaluable patients, supporting continued development in the more severe PH-ILD subgroup.
• A Phase 2b trial in PH-ILD is scheduled to start in mid-2026, with topline data expected in the first quarter of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180926PRIMZONEFULLFEED9722125) on May 18, 2026, and is solely responsible for the information contained therein.